missing translation for 'onlineSavingsMsg'
Learn More
Learn More
R&D Systems™ Recombinant Human IFN-gamma Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
Brand: R&D Systems™ 285-IF-100/CF
This item is not returnable.
View return policy
Description
Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129. The ED50 for this effect is 0.15-0.75 ng/mL.Specifications
| Lyophilized from a 0.2μm filtered solution in Sodium Succinate, Mannitol and Tween™ 80. | |
| 16.9 kDa | |
| 100 μg | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution. | |
| Recombinant |
| 3458 | |
| IFN-gamma | |
| E. coli-derived human IFN-gamma protein Gln24-Gln166 with an N-terminal Met | |
| Unconjugated | |
| 97%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction